SFA
AZN icon

Semmax Financial Advisors’s AstraZeneca AZN Stock Holding History

Semmax Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$4K – 350
2019
Q1 		$4K Sell
50
-7,329
-99% -$578K ﹤0.01% 363
2018
Q4 		$560K Buy
+7,379
New +$576K 0.44% 60

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Semmax Financial Advisors's AZN Position: Q2 2019 in Review

Semmax Financial Advisors sold out of AstraZeneca (AZN) in Q2 2019, closing a stake of 50 shares — an estimated $4K sold.

Semmax Financial Advisors first reported a position in AZN in Q4 2018 and held it in 2 quarters. The position peaked at $560K in Q4 2018. 546 funds tracked by Wall St. Rank hold AZN as of Q2 2019.

  • Semmax Financial Advisors reported no remaining AstraZeneca position as of Q2 2019 after selling out during the quarter.
  • Semmax Financial Advisors sold 50 AstraZeneca shares in Q2 2019, an estimated $4K.
  • Semmax Financial Advisors first reported a position in AstraZeneca in Q4 2018 and held it in 2 quarters.
  • Semmax Financial Advisors's AstraZeneca position peaked at $560K in Q4 2018.
  • 546 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2019.

Based on Semmax Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.